If you run a practice that infuses biologics like Remicade, Inflectra, or Simponi Aria, you already know the fear. You buy the drug, you infuse the patient, and three weeks later the claim comes back denied. The vial is gone. The patient is fine. Your practice is out thousands of dollars.
This is the buy-and-bill trap. Under buy-and-bill, your practice purchases the drug first, infuses it, and then bills the insurance company to get paid back. When the claim gets denied, there is no do-over. You cannot un-infuse the drug. I spent ten years in medical billing watching this exact scenario drain practices, and almost every time, the denial traced back to one of six predictable causes.
Why Infusion Denials Hurt More Than Other Denials
A denied office visit claim is annoying. A denied infusion drug claim is expensive. Biologics like Remicade and Simponi Aria can cost thousands of dollars per vial or per dose. When the insurance company denies the claim, your practice has already spent that money on inventory that cannot be resold or returned.
That is why getting ahead of infusion drug denial prior authorization problems matters so much more here than in almost any other part of your revenue cycle work (the ongoing process of getting paid for care, from scheduling through final payment).
Six Reasons Infusion Drugs Get Denied
Most infusion denials come from one of these six causes. If you recognize your practice in more than one, you are not alone, and it is fixable.
- Missing or expired prior authorization. Prior authorization (PA) is the insurance company's advance approval required before certain drugs or services are covered. Many infusion PAs are only good for a set number of months or a set number of visits. If the infusion happens after the approval window closes, the claim denies even though the original PA was done correctly.
- Step therapy requirements. Step therapy means the payer requires the patient to try and fail a cheaper drug before it will cover the more expensive one. If the chart does not clearly document that the patient already tried the required step drug, the payer denies the newer biologic, even if it is clinically the right choice.
- The payer switched to a preferred biosimilar. A biosimilar is a biologic drug that is highly similar to an original brand-name biologic, often sold at a lower cost. Payers frequently update their preferred drug list and switch coverage from the brand to a biosimilar, or from one biosimilar to another, sometimes with little notice. If your practice infuses the drug the PA was written for last year, but the payer quietly moved to a different preferred product, the claim can deny.
- Site-of-care rules pushing infusions out of your office. Some payers now require certain infusions to happen at a hospital outpatient department, an infusion center, or even the patient's home, instead of your office. This is called a site-of-care requirement. If your practice is not an approved site for that specific drug and that specific plan, the claim denies regardless of how well everything else was documented.
- NDC or units mismatch. The NDC (National Drug Code) is the specific product identifier for the exact drug and vial size used. If the NDC billed does not match the vial actually administered, or if the billed units do not match the authorized dose, the claim can deny on a simple data mismatch, even when the clinical care was appropriate.
- Dose over the authorized amount. Many prior authorizations approve a specific dose based on the patient's weight or clinical protocol. If the physician adjusts the dose upward during treatment and the new dose exceeds what was authorized, the extra amount, or sometimes the entire claim, gets denied.
For a deeper look at how NDCs, units, and modifiers interact specifically for infliximab biosimilars, I wrote a full breakdown here: Infliximab Biosimilar Billing: Codes, NDCs, and Modifiers.
Why Each of These Is Extra Painful for Buy-and-Bill Practices
With most denials, you lose the time it takes to appeal. With infusion drug denials, you often lose the cost of the drug itself, plus the time. A denied office visit costs you a resubmission. A denied Remicade infusion can cost you the full price of the vial, which many practices never recover even after a successful appeal, because resubmission timelines and appeal windows vary by payer.
That financial exposure is exactly why prior authorization speed and accuracy matter so much more for infusion drugs than for almost anything else you bill. If your team is already fighting slow turnaround times on PA approvals in general, this checklist can help: How to Speed Up Prior Authorization: A Biller's Checklist.
The Check-Before-You-Infuse Habit
You cannot prevent every denial, but you can catch most of these six causes with one simple habit, done by a human or an AI agent, every single time, before the patient sits down for infusion:
- Confirm the PA is still active for this visit date, not just active when it was originally approved.
- Confirm the drug on the PA matches the drug in the vial, including the specific biosimilar name if applicable.
- Confirm the payer has not published a new step therapy or preferred product policy since the PA was approved.
- Confirm your office is still an approved site of care for this drug under this specific plan.
- Confirm the dose ordered today matches the dose on the authorization, and flag any increase before infusing.
This five-point check takes a few minutes per patient. Compare that to the hours and dollars lost reversing a denial after the drug is already gone. If your practice is deciding whether this kind of pre-infusion check should sit with an in-house biller, an outside billing company, or an AI agent that runs it automatically before every scheduled infusion, this comparison walks through the tradeoffs honestly: In-House Biller vs Billing Company: An Honest Comparison.
Where to Go From Here
If infusion denials are a recurring problem in your practice, it is worth stepping back and looking at your denial pattern across all your claims, not just infusions. We built a free Billing Health Check at audit.getautomatedrcm.com that looks at where your denials are actually coming from, so you are fixing the real cause instead of guessing.
Infusion drugs are one of the few places in medical billing where a denial is not just a paperwork headache. It is real money already spent. A consistent check-before-you-infuse habit is the cheapest insurance policy your practice can buy.
Frequently Asked Questions
Why does insurance deny Remicade or Simponi Aria even after prior authorization was approved?
Prior authorizations often expire after a set number of months or visits, and payers sometimes switch their preferred drug or biosimilar after the original approval was issued. If the infusion happens after the authorization window closes, or the drug administered no longer matches the payer's current preferred product, the claim can deny even though the original approval was correct.
What is step therapy and how does it cause infusion drug denials?
Step therapy is a payer requirement that a patient try a less expensive drug first and fail to respond before a more expensive biologic like Remicade will be covered. If the patient's chart does not clearly document that the required step drug was tried, the payer can deny the infusion claim regardless of clinical judgment.
What does site of care mean for infusion billing?
Site of care refers to payer rules about where an infusion must take place, such as a hospital outpatient department, an infusion center, or the patient's home, instead of a physician's office. If a payer requires a different site of care for a specific drug and plan, claims billed from the office can be denied even when everything else about the authorization is correct.
How can a practice prevent infusion drug denials before they happen?
The most effective method is a short check-before-you-infuse review done for every scheduled patient: confirming the prior authorization is still active, the drug and dose match the approval, the payer has not changed its preferred product policy, and the office is still an approved site of care. Doing this check before the infusion, rather than after the claim denies, protects the practice from losing the cost of an already-purchased drug.